Open AccessNeurodevelopmental Outcomes of Preterm Infants With Retinopathy of Prematurity by Treatment
Author(s) -
Girija Natarajan,
Seetha Shankaran,
Tracy L. Nolen,
Amaanti Sridhar,
Kathleen A. Kennedy,
Susan R. Hintz,
Dale L. Phelps,
Sara B. DeMauro,
Waldemar A. Carlo,
Marie G. Gantz,
Abhik Das,
Rachel G. Greenberg,
Noelle Younge,
Joseph M. Bliss,
Ruth Seabrook,
Pablo J. Sánchez,
Myra H. Wyckoff,
Edward F. Bell,
Betty R. Vohr,
Rosemary D. Higgins
Publication year - 2019
Publication title -
pediatrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.611
H-Index - 345
eISSN - 1098-4275
pISSN - 0031-4005
DOI - 10.1542/peds.2018-3537
Subject(s) - medicine , interquartile range , retinopathy of prematurity , bayley scales of infant development , gestational age , odds ratio , pediatrics , bevacizumab , bronchopulmonary dysplasia , birth weight , toddler , confidence interval , pregnancy , chemotherapy , biology , developmental psychology , psychiatry , psychology , genetics , cognition , psychomotor learning
Among extremely preterm infants, we evaluated whether bevacizumab therapy compared with surgery for retinopathy of prematurity (ROP) is associated with adverse outcomes in early childhood.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom